D
Dimitris Papanicolaou
Researcher at Novartis
Publications - 20
Citations - 3212
Dimitris Papanicolaou is an academic researcher from Novartis. The author has contributed to research in topics: Placebo & Myostatin. The author has an hindex of 12, co-authored 20 publications receiving 2649 citations. Previous affiliations of Dimitris Papanicolaou include Johns Hopkins University School of Medicine & Merck & Co..
Papers
More filters
Journal ArticleDOI
Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia.
Roger A. Fielding,Bruno Vellas,William J. Evans,Shalender Bhasin,John E. Morley,Anne B. Newman,Gabor Abellan van Kan,Sandrine Andrieu,Juergen M. Bauer,Denis Breuille,Tommy Cederholm,Julie Chandler,Capucine De Meynard,Lorenzo M. Donini,Tamara B. Harris,Aimo Kannt,Florence Keime Guibert,Graziano Onder,Dimitris Papanicolaou,Yves Rolland,Daniel Rooks,Cornel C. Sieber,Elisabeth Souhami,Sjors Verlaan,Mauro Zamboni +24 more
TL;DR: Sarcopenia should be considered in all older patients who present with observed declines in physical function, strength, or overall health, and patients who meet these criteria should further undergo body composition assessment using dual energy x-ray absorptiometry with sarcopenia being defined using currently validated definitions.
Journal ArticleDOI
A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia.
Dimitris Papanicolaou,Dimitris Papanicolaou,S. N. Ather,H. Zhu,Y. Zhou,Jeannine Lutkiewicz,Boyd B. Scott,Julie Chandler +7 more
TL;DR: The MK-0773-induced increase in LBM did not translate to improvement in strength or function vs. placebo, and the improvement of strength and physical function in the placebo group could be at least partly attributed to protein and vitamin D supplementation.
Journal ArticleDOI
Performance-based or self-report measures of physical function: which should be used in clinical trials of hip fracture patients?
Nancy K. Latham,Vinay Mehta,Allison Martin Nguyen,Alan M. Jette,Sippy Olarsch,Dimitris Papanicolaou,Julie Chandler +6 more
TL;DR: Findings reveal that the validity, sensitivity, and responsiveness of self-report measures of physical function are comparable to performance-based measures in a sample of patients followed after fracturing a hip.
Journal ArticleDOI
Once-weekly dose of 8400 IU vitamin D3 compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency
Paul Lips,Neil Binkley,Michael Pfeifer,Robert R. Recker,Suvajit Samanta,D Cohn,Julie Chandler,Elizabeth Rosenberg,Dimitris Papanicolaou +8 more
TL;DR: In this article, the effects of a weekly dose of 8400 IU vitamin D(3) on postural stability, muscle strength, and safety were investigated in a double-blind trial, where subjects aged > or =70 y with serum 25-hydroxyvitamin D [25(OH)D] concentrations or =6 ng/mL were randomly assigned to receive either 8400 or placebo.
Journal ArticleDOI
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
Michael G. Hanna,Umesh A. Badrising,Olivier Benveniste,Thomas E. Lloyd,Merrilee Needham,Hector Chinoy,Masashi Aoki,Pedro Machado,Christina Liang,Katrina Reardon,Marianne de Visser,Dana P. Ascherman,Richard J. Barohn,Mazen M. Dimachkie,James Miller,John T. Kissel,Bjorn Oskarsson,Nanette C. Joyce,P. Van den Bergh,Jonathan Baets,J. De Bleecker,Chafic Karam,William S. David,Massimiliano Mirabella,Sharon P. Nations,Hans H. Jung,Elena Pegoraro,Lorenzo Maggi,Carmelo Rodolico,Massimiliano Filosto,Aziz Shaibani,Kumaraswamy Sivakumar,Namita Goyal,Madoka Mori-Yoshimura,Satoshi Yamashita,Naoki Suzuki,Masahisa Katsuno,Ken-ya Murata,Hiroyuki Nodera,Ichizo Nishino,Carla D. Romano,Valerie S.L. Williams,John Vissing,Lixin Zhang Auberson,Min Wu,Ana de Vera,Dimitris Papanicolaou,Anthony A. Amato +47 more
TL;DR: The safety, efficacy, and tolerability of bimagrumab-a fully human monoclonal antibody-in individuals with inclusion body myositis were assessed and no significant adverse cardiac effects were recorded on electrocardiography or echocardiography.